Related Experiment Videos
[Calcium antagonists: effect on peripheral and coronary hemodynamics]
Insights
Calcium channel blockers affect the heart and circulation through direct and indirect actions. Their impact on cardiac function varies, influencing coronary blood flow and potentially benefiting patients with coronary artery disease.
Area of Science:
- Cardiovascular Pharmacology
- Human Physiology
Context:
- Calcium channel blockers (calcium antagonists) exert complex effects on the cardiovascular system.
- Understanding these effects is crucial for managing various cardiac conditions.
Purpose:
- To elucidate the direct and indirect actions of calcium channel blockers on the human heart and circulation.
- To analyze their impact on myocardial contractility, systemic vascular resistance, and coronary blood flow.
Summary:
- Direct administration into the coronary circulation causes negative inotropic effects on the myocardium.
- Systemic administration leads to decreased vascular resistance and blood pressure, with variable effects on cardiac function due to baroreceptor reflexes.
- These drugs induce vasodilation and increase coronary blood flow, notably in poststenotic regions, offering potential therapeutic benefits.
Impact:
- Calcium antagonists can depress, maintain, or enhance myocardial contractility based on the patient's cardiac status.
- The unique enhancement of coronary blood flow in poststenotic areas suggests potential for treating coronary artery disease and angina pectoris.
Abstract:
The effects of calcium channel blocking drugs, so-called calcium antagonists, on the human heart and circulation are a composite of various direct (cardiac) and indirect (peripheral vascular) actions. When injected into the coronary circulation, calcium antagonists produce a direct negative inotropic effect on the human myocardium that is characterized by a depression of DP/DT and left ventricular ejection fraction, an increase in end-diastolic pressure and a decrease in systolic pressure. When administered intravenously, sublingually or orally, all calcium antagonists cause a fall in systemic vascular resistance and a drop in systemic arterial pressure, but their actions on cardiac function are less uniform. In particular, a baroreceptor-mediated reflex increase in betaadrenergic tone that is triggered by the fall in blood pressure and depends in degree on the compound and the route of administration, may counterbalance or override the direct negative inotropic effect. As a result, myocardial contractility and ventricular performance can be depressed, unchanged, or even enhanced by calcium antagonists, depending on the underlying status of myocardial function. In the coronary circulation, calcium antagonists, whether administered directly or indirectly (systemically), elicit relaxation of vascular smooth muscle and vasodilatation that is associated with an increase in global coronary blood flow. In contrast to the effects of other vasodilating drugs, however, flow is found to be enhanced not only in myocardial regions supplied by normal coronaries but also in poststenotic areas, at rest as well as with rapid atrial pacing. Although not entirely understood, this latter phenomenon may be of particular interest for the treatment of patients with coronary disease and angina pectoris.